《医用甲壳质可吸收缝合线》创业计划书目录1．执行总结············································02．项目背景············································23．市场机会············································34．公司战略············································75．市场营销············································96．生产管理············································137．投资分析············································158．财务分析············································189．管理体系············································2210．机遇与风险········································2311．风险资本的退出···································24附录1．市场容量估算·······································252．市场调查和定性分析·······························263．财务附表············································301. 执行总结1.1.公司甲壳质材料讨论&开发 XX 公司是一个提议中的公司，它拥有甲壳质纤维制备的专利技术，提倡科技为本的绿色生活新理念，为人类提供尽善尽美的天然生物产品。我国医用缝合线每年约有 15 亿人民币的市场需求，其中可吸收缝合线约有 7.5 亿。公司成立初期生产医用甲壳质可吸收缝合线，以满足迅速进展的可吸收缝合线市场的需求，使用投资建厂解决方案，针对解决 PGA（Polyglycolic Acid 聚乙二醇酸）类可吸收缝合线大部分依赖进口、价格昂贵、影响提高人们医疗水平的问题。公司注重短期目标与长远战略的结合，中长期目标将逐步拓宽产品领域，涉足甲壳质医用抗菌材料、药物缓释材料、人造器官、化妆品、...
